RCUS
Arcus Biosciences Inc
NYSE: RCUS · HEALTHCARE · BIOTECHNOLOGY
$24.13
-2.70% today
Updated 2026-04-29
Market cap
$3.03B
P/E ratio
—
P/S ratio
12.27x
EPS (TTM)
$-3.29
Dividend yield
—
52W range
$7 – $29
Volume
1.3M
Arcus Biosciences Inc (RCUS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-142.90%
Operating margin
-345.40%
ROE
-63.30%
ROA
-21.10%
Debt/equity
0.25x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | $0.00 | $-17.97M | — | — | — |
| 2017 | $1.41M | $-53.08M | 100.00% | -3,782.09% | -3,756.69% |
| 2018 | $8.35M | $-49.59M | 100.00% | -656.76% | -593.73% |
| 2019 | $15.00M | $-75.93M | 100.00% | -591.39% | -506.21% |
| 2020 | $78.00M | $-123.00M | 100.00% | -158.97% | -157.69% |
| 2021 | $383.00M | $53.00M | 100.00% | 14.10% | 13.84% |
| 2022 | $112.00M | $-267.00M | 100.00% | -250.00% | -238.39% |
| 2023 | $117.00M | $-307.00M | 100.00% | -290.60% | -262.39% |
| 2024 | $258.00M | $-283.00M | 100.00% | -127.91% | -109.69% |
| 2025 | $247.00M | $-353.00M | 95.95% | -156.28% | -142.91% |